

## BC PEDIATRIC SOCIETY > ROUTINE IMMUNIZATION SCHEDULE 2018

Please see <u>www.immunizebc.ca</u> for further immunization information or BC Centre for Disease Control Immunization

(Manual http://www.bccdc.ca/health-professionals/clinical-resources/communicable-disease-control-manual)

ROUTINE

## > For high risk children or special populations please refer to BCPS HIGH RISK IMMUNIZATION SCHEDULE here

| AGE       | PROVINCIAL VACCINE   | ROUTE | OTHER VACCINES & COMMENTS   |
|-----------|--|-------|---|
| 2 months  | Rotavirus (Rotateq <sup>®</sup> ) <sup>1</sup>                       | PO    | Give first.   |
|           | DTaP-HB-IPV-Hib (Infanrix hexa™)                                     | IM    | <u>See Factsheet: Hepatitis A – Local Risks</u>   |
|           |  |       | See Factsheet: Travel Vaccines – Enterically Borne  |
|           | Pneumococcal conjugate (Prevnar <sup>®</sup> 13)                     | IM    | <ul> <li>Consider Menveo for travelers beginning at 2 months of age if meningococcal vaccine is indicated.<sup>2</sup></li> <li><u>See Factsheet: Meningococcal Disease</u></li> <li>A non-publicly funded meningococcal B vaccine is now approved for use in Canada. NACI recommends the multicomponent meningococcal serogroup B (4CMenB) vaccine may be considered on an individual basis for children 2 months of age, and should be considered for active immunization of individuals at 2 months of age at high risk.<sup>3, 4</sup></li> </ul> |
|           | Men-C conjugate (NeisVac-C®)   | IM    |   |
|           |  |       | See Factsheet: Meningococcal B Vaccine: What Parents Need to Know   |
| 4 months  | 2 <sup>nd</sup> Rotavirus (Rotateq <sup>®</sup> ) <sup>1</sup>       | PO    | Give first.   |
|           | 2 <sup>nd</sup> DTaP-HB-IPV-Hib (Infanrix hexa™)                     | IM    |   |
|           | 2 <sup>nd</sup> Pneumococcal conjugate (Prevnar <sup>®</sup> 13)     | IM    |   |
| 6 months  | 3 <sup>rd</sup> Rotavirus (Rotateq®) <sup>1</sup>                    | PO    | Give first.   |
|           | 3 <sup>rd</sup> DTaP-HB-IPV-Hib (Infanrix hexa™)                     | IM    |   |
|           | Influenza  | IM    | <ul> <li>Annual influenza immunization for children beginning at 6 months (two doses in 1st year of vaccine receipt).<br/>Publicly funded for those aged 6 – 59 months and for other children with, or close contacts of those with high<br/>risk medical conditions.<sup>1</sup></li> </ul>  |
|           |  |       | See Factsheet: Influenza  |
|           | Hepatitis A<br>(publicly funded for Aboriginal Infants) <sup>2</sup> | IM    | <ul> <li>Hepatits A Vaccine is publicly funded up to 18 years of age for Aboriginal children only.<sup>2</sup></li> <li><u>See Factsheet: Hepatitis A – Local Risks</u></li> </ul>  |
| 12 months | 2 <sup>nd</sup> Men-C conjugate (NeisVac-C <sup>®</sup> )            | IM    | Annual influenza immunization   |
|           | 3 <sup>rd</sup> Pneumococcal conjugate (Prevnar <sup>®</sup> 13)     | IM    |   |
|           | MMR  | SC    |   |
|           | Varicella (Varivax <sup>®</sup> III or Varilrix <sup>®</sup> )       | SC    |   |
| 18 months | 4 <sup>th</sup> DTaP-IPV-Hib   | IM    | Annual influenza immunization   |
|           | 2 <sup>nd</sup> Hepatitis A (Aboriginal Infants) <sup>2</sup>        | IM    |   |
| 4-6 years | Tdap-IPV   | IM    | • Annual influenza immunization up to 59 months and consider annual influenza immunization for 5 years and older.   |
|           | Varicella/MMR (ProQuad <sup>®</sup> , Priorix-tetra <sup>®</sup> )   | SC    | <u>See Factsheet: Influenza</u>   |



Please see www.immunizebc.ca for further immunization information or **BC Centre for Disease Control Immunization** 

(Manual http://www.bccdc.ca/health-professionals/clinical-resources/communicable-disease-control-manual)

ROUTINE

| AGE                   | PROVINCIAL VACCINE   | ROUTE | OTHER VACCINES & COMMENTS   |
|-----------------------|--|-------|---|
| 11 years<br>(Grade 6) | Nonovalent HPV (Gardasil®9)  | IM    | <ul> <li>Gardasil<sup>®</sup>9 is publicly funded for grade 6 boys and girls, females born after 2005 and HIV+ females 9-26 yrs of age.<sup>2</sup></li> </ul>  |
|                       |  |       | <ul> <li>HPV vaccine is publicly funded for high risk males 9-26 years, including those who have sex with men,<br/>street involved youth, boys who may be questioning their sexual identity, and youth in custody or in care of<br/>Ministry of Children and Families, females born 1994 - 2004.<sup>2</sup></li> </ul> |
|                       |  |       | <ul> <li>Recommended for older females and women up to age 45 and all boys age 9 to 26 years. Not publicly funded.<sup>2</sup> It is available for purchase from most pharmacies and travel clinics.</li> </ul>   |
|                       |  |       | • See BCPS Factsheet: Human Papillomavirus (HPV)  |
|                       | Varicella (Varivax <sup>®</sup> III or Varilrix <sup>®</sup> )<br>if susceptible | SC    | Children who have never had a dose receive 2 doses, the 2nd at least 3 months after dose 1.   |
|                       |  |       | <ul> <li>Children who received 1 dose at a younger age only need 1 dose.</li> </ul>   |
|                       |  |       | Children diagnosed with chicken pox after 1 year of age do not need MMRV vaccine.   |
|                       |  |       | <ul> <li>Consider Men-A/C/YW for travelers for whom meningococcal vaccine is indicated. Menveo<sup>®</sup>, Menactra<sup>®</sup> or<br/>Nimenrix<sup>®</sup>.<sup>1</sup></li> </ul>  |
|                       |  |       | Consider annual influenza immunization.   |
| 14 years<br>(Grade 9) | Tdap (Adacel <sup>®</sup> ) then every 10 years                                  | IM    | • Males and females initiating Gardasil <sup>®</sup> at age 15 years or older should receive a 3 dose series. <sup>2</sup>  |
|                       | Meningococcal-ACYW   | IM    | See Factsheet: Meningococcal Disease  |

## **HIGH RISK INDIVIDUALS**

Hepatitis A, HPV, Meningococcal and Pneumococcal vaccine recommendations for immunization of high risk including immunocompromised, immunosuppressd or children with other health conditions, travelers, aboriginal or special populations may be found at:

- 1) BC Centre for Disease Control Immunization Program Manual Section VII Biological Products
- 2) Section III Immunization of Special Populations

See precautions and advice when administering live vaccines to immunosuppressed children.

<sup>7</sup> First dose of Rotateg<sup>®</sup> vaccine to be given no later than 20 weeks less 1 day of age. Third dose to be administered by 8 months less zero days. Minium 4 weeks between each dose. If any dose in the series is RotaTeg® or the product is unknown, a total of 3 doses of vaccine should be administered.

http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/Chapter%202%20-%20Imms/SectionIIA ImmunizationSchedules.pdf <sup>2</sup> BC Centre for Disease Control. 2018. Communicable Disease Control Immunization ProgramSection VII – Biological Products <u>http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/Chapter%202%20-%20Imms/SectionVII\_BiologicalProducts.pdf</u>

<sup>3</sup> The Recommended Use of the Multicomponent Meningococcal B (4CMenB) Vaccine in Canada. http://www.phac-aspc.gc.ca/naci-ccni/mening-4cmenb-exec-resum-eng.php

<sup>4</sup> Meningococcal B vaccine is publicly funded for case contacts only. Meningococcal B dose schedule available at: http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/Chapter%202%20-%20Imms/SectionVII\_BiologicalProducts.pdf